---
layout: default
title: Granisetron
parent: Model Prediction Only (L5)
nav_order: 438
evidence_level: L5
indication_count: 10
---

# Granisetron
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Granisetron: From 5-HT3 Antagonist Antiemetic Use to Manic Bipolar Affective Disorder

## One-Sentence Summary

Granisetron is a selective 5-HT3 receptor antagonist, a class used as an antiemetic.
The TxGNN model predicts it may be effective for **manic bipolar affective disorder**,
but currently **0 clinical trials** and **0 publications** support this direction, so it remains a model prediction only.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Approved indication text was not supplied for the Canadian licences (the drug class is a 5-HT3 antagonist antiemetic) |
| Predicted New Indication | Manic bipolar affective disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank. Based on known information, granisetron is a selective 5-HT3 receptor antagonist. Its use in its original setting rests on blocking serotonin signalling through this receptor.

The link to mania is speculative. It would rely on 5-HT3 blockade indirectly modulating serotonergic and dopaminergic signalling, both of which are implicated in mood disorders. No trials or publications were supplied to test this idea.

The very high TxGNN score (0.996) reflects proximity in the knowledge graph, not confirmed biology. The score should be read as a hypothesis generator, not as evidence of efficacy.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 02322765 | GRANISETRON HYDROCHLORIDE INJECTION |
| 02452359 | NAT-GRANISETRON |
| 02308894 | APO-GRANISETRON |

---

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found in the supplied data.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the model score (Evidence Level L5). There are no trials or publications, and the mechanistic link to mania is speculative. Progressing further is not justified at this stage.

**To proceed, the following is needed:**
- A targeted literature search on 5-HT3 antagonists in bipolar mania and mood disorders, to determine whether any preclinical or clinical signal exists
- Mechanism of action data from DrugBank, to support the mechanistic-link analysis
- The Health Canada product monograph (warnings, contraindications, approved indications), which is required before any safety screening
- If the literature search is negative, consider shifting attention to other high-scoring candidates with more plausible serotonergic rationale, namely Tourette syndrome and trichotillomania, both currently flagged as research questions

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

